ANDA 210764, held by ANDA Repository. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 210764 (Methylphenidate Hydrochloride), held by ANDA Repository, was first approved by FDA on Apr 10, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 10, 2020 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters